학술논문

Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M-Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report.
Document Type
journal article
Source
Journal of Thoracic Oncology; May2019, Vol. 14 Issue 5, p933-939, 7p
Subject
Language
ISSN
15560864